Form 4: Atea Pharmaceuticals Executive Wayne Foster Reports Stock Transactions

Wayne Foster, EVP and Chief Accounting Officer of Atea Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On January 31, 2025, Wayne Foster, EVP and Chief Accounting Officer of Atea Pharmaceuticals, engaged in transactions involving the company's stock.
• Foster acquired 8,000 shares of common stock and disposed of 33,333 shares related to restricted stock units.
• He also acquired 120,100 stock options exercisable in monthly installments until January 31, 2029.
• Following these transactions, Foster directly owns 50,128 shares of common stock, 8,000 restricted stock units, and 120,100 stock options.
• The transactions included the vesting of 33,333 restricted stock units and the acquisition of 8,000 shares upon the satisfaction of performance criteria related to performance restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions without indicating a positive or negative outlook.

Positives

• The vesting of restricted stock units and acquisition of shares upon meeting performance criteria could be seen as a positive indicator of the company's performance.

Future Outlook

The stock options vest in forty-eight (48) equal monthly installments following January 31, 2025, such that the option is fully vested on January 31, 2029.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of shares available in the market.

Key Dates